20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Adlai Nortye Ltd. American Depositary Shares (ANL) operates in the BIOTECHNOLOGY industry and is headquartered in Singapore, Singapore with about 109 employees. Its market capitalization is roughly $1 billion. In the fiscal year ended 2025-12-31, ANL reported $5M in revenue and ($36M) in net income.
Adlai Nortye Group Ltd., a clinical-stage biopharmaceutical company, engages in the discovery and development of cancer therapies. The company's pipeline centers on RAS-targeting therapies and next-generation cancer immunotherapies.
Interactive charts & full statements → Open the ANL valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $15M | $5M | $0M | $5M | $0M | $46M | — | — |
| Gross Profit | $15M | $5M | ($2M) | $5M | ($2M) | $46M | ($2M) | ($1M) |
| Gross Margin % | 100.0% | 100.0% | — | 100.1% | — | 100.0% | — | — |
| Operating Income (EBIT) | ($6M) | ($36M) | ($53M) | ($73M) | ($67M) | ($9M) | ($26M) | ($19M) |
| Operating Margin % | -39.3% | -714.0% | — | -1452.3% | — | -18.9% | — | — |
| Net Income | ($5M) | ($36M) | ($52M) | ($109M) | ($59M) | ($57M) | ($63M) | ($18M) |
| Net Margin % | -36.4% | -710.6% | — | -2186.5% | — | -124.0% | — | — |
| EBITDA | ($5M) | ($33M) | ($48M) | ($106M) | ($56M) | ($54M) | ($60M) | ($16M) |
| Earnings Per Share (EPS) | $-0.34 | $-3.33 | $-4.87 | $-16.05 | $-4.78 | $-4.61 | $-7.47 | $-2.10 |
| Shares Outstanding (M) | 16M | 11M | 11M | 7M | 12M | 12M | 8M | 8M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $7M | $7M | $2M | $1M | $1M | $2M | $2M | $0M |
| Gross Profit | $7M | $7M | $2M | $1M | $1M | $2M | $2M | ($1M) |
| Gross Margin % | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | — |
| Operating Income (EBIT) | ($3M) | ($3M) | ($8M) | ($15M) | ($15M) | ($18M) | ($20M) | ($17M) |
| Operating Margin % | -39.3% | -39.3% | -330.5% | -1962.6% | -1962.6% | -708.5% | -808.5% | — |
| Net Income | ($3M) | ($3M) | ($9M) | ($14M) | ($14M) | ($13M) | ($15M) | ($63M) |
| Net Margin % | -36.4% | -36.4% | -343.9% | -1853.2% | -1853.2% | -529.1% | -616.2% | — |
| EBITDA | ($3M) | ($3M) | ($8M) | ($14M) | ($14M) | ($17M) | ($20M) | ($63M) |
| Earnings Per Share (EPS) | $-0.17 | $-0.17 | $-0.81 | — | — | — | — | — |
| Shares Outstanding (M) | 16M | 16M | 11M | — | — | — | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($32M) | ($34M) | ($52M) | ($57M) | ($43M) | ($3M) | ($35M) | ($15M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $1M | $1M | $2M | $0M |
| Free Cash Flow (FCF) | ($32M) | ($34M) | ($52M) | ($57M) | ($44M) | ($4M) | ($36M) | ($15M) |
| FCF Margin % | -220.4% | -674.5% | — | -1138.0% | — | -9.1% | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($8M) | ($8M) | ($9M) | ($8M) | ($8M) | ($12M) | ($14M) | ($14M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($8M) | ($8M) | ($9M) | ($8M) | ($8M) | ($12M) | ($14M) | ($14M) |
| FCF Margin % | -104.6% | -107.1% | -370.4% | — | — | — | -1912.3% | -1912.3% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $248M | $34M | $71M | $130M | $73M | $132M | $37M | $11M |
| Cash & Cash Equivalents | $133M | $24M | $61M | $91M | $43M | $64M | $24M | $6M |
| Total Liabilities | $34M | $43M | $46M | $55M | $314M | $317M | $168M | $80M |
| Total Debt (Short + Long-Term) | $26M | $25M | $27M | $31M | $5M | $11M | $9M | $11M |
| Total Shareholders' Equity | $215M | ($8M) | $25M | $75M | ($241M) | ($185M) | ($132M) | ($69M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive ANL viewer.
About TickerBase · Data methodology & sources · Privacy · Terms